ISPOR 17th Annual International Meeting
June 2-6, 2012, Washington, DC, USA
Search:
Value-based Decision Making in Rheumatic Disease : What does it mean for pharmacists ?
Médicaments Issus des Biotechnologies : Différencier Les Prix selon la Valeur
Comments on : Performance-Based Risk-Sharing Arrangements - Good practice for design, implementation and evaluation. An ISPOR Task force review
EUnetHTA : Draft Guidelines - Endpoints used for REA of pharmaceuticals HEALTH-RELATED QUALITY OF LIFE and UTILITY MEASURES
Home
Publications
Publications 2010-2014
Launois R.
Comparative Effectiveness Research versus Analyse Coût efficacité
Evaluation et Prix des Technologies Médicales : France - Etats Unis, Berkeley University of California - Université Paris Descartes, Paris, 19 Mai 2011
(
PDF, 320.4 ko
)
Value-based Decision Making in Rheumatic Disease : What does it mean for pharmacists ?
